Drug Interactions between lutetium lu 177 dotatate and pasireotide

Medications like pasireotide can reduce the effectiveness of lutetium Lu 177 dotatate depending on when they are administered relative to the dose of lutetium Lu 177 dotatate. In general, long-acting formulations of these medications (usually those given by intramuscular injection) should be discontinued for at least 4 weeks and short-acting formulations should be discontinued for at least 24 hours prior to each dose of lutetium Lu 177 dotatate. You may use pasireotide following an infusion of lutetium Lu 177 dotatate, but it is important to adhere to the dosing schedules exactly as prescribed so as to minimize the risk for interaction. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.